Download full report with analyst certification and important disclosures
Aug 6 2026, 07:10 IST/BST
Glanbia
H1-26 results: beat and raise
DAVY VIEW
Strong execution across all three platforms drove a 5.4% first-half EBITDA beat for Glanbia and supports a meaningful upgrade to full-year guidance. Optimum Nutrition remained a standout performer, with estimated organic sales growth in Q2 accelerating to 31%. We expect to upgrade our full-year EPS forecast by 4-5% towards 160c. The business is executing to a high standard.
